Good Manufacturing, Good Laboratory or Good Clinical Practice regulations all apply to laboratory testing, but they each serve different purposes with responsibilities being handled by different people. In the last of three articles we explore GCP.

In a shift of thinking, governments in the EU and UK are now considering reversing the ban on vaccinating poultry against bird flu. This is in response to the largest avian flu epidemic so far observed in Europe, with 2,467 outbreaks in poultry recorded by the European Food Safety Authority (Efsa) in the 2021-2022 season, and an unprecedented number of highly pathogenic avian influenza (HPAI) virus variants detected.

In Vivo and In Vitro Specialist Appointed Head of Scientific as Company Enters New Phase of Growth

Good Manufacturing, Good Laboratory or Good Clinical Practice regulations all apply to laboratory testing, but they each serve different purposes with responsibilities being handled by different people. In the second of three articles we explore GLP.

Back from a fantastic week in Hong Kong with our Asia-based business partners and staff.

Good Manufacturing, Good Laboratory or Good Clinical Practice regulations all apply to laboratory testing, but they each serve different purposes with responsibilities being handled by different people.  In this first of three brief articles, we look at the role of GMPs.

The protection of the public and the environment from unsafe chemicals rests on the shoulders of regulatory authorities who must rely on the data and results of toxicological and other testing from commercial research, development, and production processes to inform and guide their regulatory approval decisions; decisions that ultimately decide the marketability and financial success or failure of these products.

Outsourcing to the right testing laboratory can give drug developers a competitive edge by maximising efficiencies and expediting the regulatory approval process. But outsourcing often comes with the risk of stepping into an unknown and untested relationship.

While evidence from psilocybin studies in rodents demonstrates long–term coping strategy and cognitive function behavioural effects that can be compared to those of traditional antidepressant treatments, a “gold-standard” protocol for assessing the behavioural effects of psychedelics has yet to be established.

Whether you are a venture capital firm looking at placing several small bets on high-risk start-up, or a later stage asset management or private equating investor considering providing the larger funding required in the later stages of clinical development, two factors are inescapable - drug development is always expensive, and the failure rate will always be high.